603 results on '"Li, Chin-Yang"'
Search Results
2. Mortality among Benzene-Exposed Workers in China
3. Measuring Text Readability by Lexical Relations Retrieved from Wordnet.
4. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
5. Contributors
6. Mastocytosis
7. Microcytosis in agnogenic myeloid metaplasia: Prevalence and clinical correlates
8. Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China
9. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
10. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
11. Risk Factors for Leukemic Transformation in Patients With Primary Myelofibrosis
12. Hematological manifestations of copper deficiency: a retrospective review
13. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis
14. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
15. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
16. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
17. Clinical Correlates of Jak2V617f Allele Burden in Essential Thrombocythemia
18. Validation and Comparison of Contemporary Prognostic Models in Primary Myelofibrosis: Analysis based on 334 patients from a single institution
19. Thalidomide Therapy in Adult Patients With Myelodysplastic Syndrome: A North Central Cancer Treatment Group phase II trial
20. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders
21. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
22. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapy
23. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
24. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: A simple CBC-based scoring system
25. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
26. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates
27. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
28. Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
29. Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia
30. The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases
31. Nonhepatosplenic Extramedullary Hematopoiesis: Associated Diseases, Pathology, Clinical Course, and Treatment
32. 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell Histiocytosis
33. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder
34. Systemic Mast Cell Disease Without Associated Hematologic Disorder: A Combined Retrospective and Prospective Study
35. Thalidomide treatment in myelofibrosis with myeloid metaplasia
36. Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia
37. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia
38. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
39. Treatment of Systemic Mast-Cell Disease with Cladribine
40. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
41. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
42. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
43. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia
44. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome
45. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia
46. Primary Localized Amyloidosis of the Urinary Bladder: A Case Series of 31 Patients
47. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates
48. Cellular Distribution of Platelet-Derived Growth Factor, Transforming Growth Factor-β, Basic Fibroblast Growth Factor, and Their Receptors in Normal Bone Marrow
49. Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms
50. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.